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Abstract: Proprotein convertase subtilisin kexin type 9 (PCSK9) is a key-
regulator of hepatic low-density lipoprotein-receptor (LDLR). PCSK9 is 
expressed in cultured smooth muscle cells (SMCs) and co-localizes with 
SMCs in human carotid atherosclerotic plaques. The present study aimed at 
comparing the neointimal lesions induced by periadventitial carotid 
placement of a non-occlusive collar in PCSK9 knock-out (PCSK9-/-) and 
wild type (WT) littermate (PCSK9+/+) mice.  Collared carotids of the 
PCSK9-/- mice showed less intimal thickening compared to WT mice 
(p<0.05), a decreased intimal media ratio (p<0.02) and tendency to higher 
lumen area. When compared with PCSK9-/-, carotid lesions of WT mice had a 
higher content of SMCs (p<0.05) and collagen (p<0.05).  No difference in 
macrophage content was detected between the two groups. SMCs freshly 
isolated from PCSK9-/-, when compared to PCSK9+/+ cells, showed higher 
levels of the contractile markers α-smooth muscle actin (α-SMA; 2.24±0.36 
fold; p<0.01) and myosin heavy chain II (MHC-II; 8.65±1.55 fold; p<0.01), 
and decreased levels of synthetic markers caldesmon (-54±14%; p<0.01). 
PCSK9-/- cells also showed in response to platelet-derived growth factor-
BB (PDGF-BB) a slower proliferation rate, and impaired migratory capacity 
and G1/S progression of the cell cycle. The reconstitution of PCSK9 
expression, by retroviral infection of PCSK9-/- SMCs, led to a 
downregulation of α-SMA (-56±2%; p<0.01) and significant induction of 
caldesmon (1.46±0.3 fold; p<0.05). Proliferation rate of SMCs PCSK9-/- 
was significantly lower compared to PCSK9 reconstituted cells. Taken 
together, the present results suggest that by sustaining SMC synthetic 
phenotype, proliferation and migration PCSK9 may play a pro-atherogenic 
role in the arterial wall. 
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Graphical Abstract
Highlights 
In response to perivascular manipulation, the neointimal formation is reduced in PCSK9-/- mice 
PCSK9 directly regulates smooth muscle cell differentiation, proliferation and migration 
The reconstitution of PCSK9 expression in SMCs PCSK9-/- determines a switch towards a synthetic phenotype 
and rescue the impaired proliferation and migration capacities of SMCs PCSK9-/- 
SMCs PCSK9-/- respond less efficiently to the proliferative and chemotactic action of PDGF-BB 
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Abstract 
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a key-regulator of hepatic low-density 
lipoprotein-receptor (LDLR). PCSK9 is expressed in cultured smooth muscle cells (SMCs) and co-
localizes with SMCs in human carotid atherosclerotic plaques. The present study aimed at 
comparing the neointimal lesions induced by periadventitial carotid placement of a non-occlusive 
collar in PCSK9 knock-out (PCSK9-/-) and wild type (WT) littermate (PCSK9+/+) mice.  Collared 
carotids of the PCSK9-/- mice showed less intimal thickening compared to WT mice (p<0.05), a 
decreased intimal media ratio (p<0.02) and tendency to higher lumen area. When compared with 
PCSK9-/-, carotid lesions of WT mice had a higher content of SMCs (p<0.05) and collagen (p<0.05).  
No difference in macrophage content was detected between the two groups. SMCs freshly 
isolated from PCSK9-/-, when compared to PCSK9+/+ cells, showed higher levels of the contractile 
markers α-smooth muscle actin (α-SMA; 2.24±0.36 fold; p<0.01) and myosin heavy chain II (MHC-
II; 8.65±1.55 fold; p<0.01), and decreased levels of synthetic markers caldesmon (-54±14%; 
p<0.01). PCSK9-/- cells also showed in response to platelet-derived growth factor-BB (PDGF-BB) a 
slower proliferation rate, and impaired migratory capacity and G1/S progression of the cell cycle. 
The reconstitution of PCSK9 expression, by retroviral infection of PCSK9-/- SMCs, led to a 
downregulation of α-SMA (-56±2%; p<0.01) and significant induction of caldesmon (1.46±0.3 fold; 
p<0.05). Proliferation rate of SMCs PCSK9-/- was significantly lower compared to PCSK9 
reconstituted cells. Taken together, the present results suggest that by sustaining SMC synthetic 
phenotype, proliferation and migration PCSK9 may play a pro-atherogenic role in the arterial wall.  
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Introduction 
Subendothelial accumulation of monocytes, lymphocytes, and some smooth muscle cell (SMC) 
progenitors from the blood and SMCs from the vessel wall, together with SMC-derived 
extracellular matrix (ECM), represent the prominent features of atherosclerotic plaques and 
restenosis after angioplasty 1-3.  
Significant difference exists between intima and media SMCs, with the latter 
predominantly expressing proteins involved in the cell contraction, such as α-smooth muscle actin 
(SMA), myosin heavy chain II (MHC-II), calponin, and SM22-α; while those found in the intima have 
a higher migratory and proliferative index, and a greater synthetic capacity for extracellular matrix, 
proteases, and cytokines 4, 5. 
A variety of atherogenic stimuli including extracellular matrix 6, cytokines, growth factors 7, 
shear stress 8, reactive oxygen species 9, and lipids 10 can facilitate the switch from “contractile” to 
“synthetic” phenotypic states. Once differentiated from “contractile” to “synthetic” phenotype, 
SMCs migrate and proliferate more readily and synthesize 25-30 times more collagen than 
contractile cells did 11. In addition, they increase lipid synthesis 12 and express higher levels of very 
low density lipoproteins (VLDL), low density lipoproteins (LDL), and scavenger receptors allowing 
more efficient lipid uptake and foam cell formation 13. 
Although a number of studies, conducted with genetically modified animals, have 
identified several signaling pathways or factors playing roles in SMC accumulation in the 
neointima, the mechanisms controlling SMC phenotypic switch are still not completely 
understood. 
Proprotein convertase subtilisin kexin type 9 (PCSK9) represents the newest 
pharmacological target for controlling the hypercholesterolemia and, two monoclonal antibodies 
with PCSK9 inhibitory activity have been recently approved for clinical use 14, 15. PCSK9 is mainly 
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synthesized by the liver, kidney and intestine, although other tissues and cell types express 
significant levels of PCSK9 16. In particular, we have previously reported that SMCs express PCSK9 
in vitro, and that PCSK9 is detectable in human atherosclerotic plaque in regions occupied by SMCs 
17. Our observation was then confirmed by Perisic et al, showing that significant levels of PCSK9 
mRNA are present in human carotid plaques and that these levels are upregulated, although not 
significantly, in comparison with control iliac arteries 18.  
While it is clear that PCSK9 is expressed in SMCs in the atherosclerotic plaque; its role on 
SMCs biology is still elusive. In the present study, we have investigated the potential role of PCSK9 
on SMC accumulation in neointimal lesions induced by perivascular carotid collar placement. This 
particular model was chosen since the vascular response that is observed after collar positioning in 
mice fed normal chow diet is mainly driven by SMC proliferation and migration processes, with 
minimal inflammation and, more importantly, the lesion size is independent from plasma 
cholesterol levels 19. Our data indicate that in vivo the absence of PCSK9 confers a partial 
protection from neointimal formation. Furthermore in vitro PCSK9 positively influences SMC 
differentiation, migration and proliferation. Altogether, the present results suggest a potential 
direct pro-atherogenic role of PCSK9 in arterial SMCs. 
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Materials and Methods 
Perivascular carotid collar placement 
PCSK9 heterozygous were kindly provided by Dr. Philippe Costet (INSERM, Nantes) 20. The colony 
was propagated by random intercrossing of heterozygous mutant mice to generate PCSK9-/- and 
PCSK9+/+ mice. Littermates male mice with PCSK9+/+ and PCSK9−/− genotypes were used in 
accordance with the Guide for the Care and Use of Laboratory Animals published by the US 
National Institutes of Health (NIH Publication No. 85-23, revised 1996). Mice were maintained on a 
normal diet (Mucedola, Milan, ITALY). Sixteen-week-old mice were anaesthetized by the 
intraperitoneal injection of Avertin (12 l/gr body weight of 2.5% solution) and subjected to 
perivascular carotid collar placement. Collars (length: 3 mm, internal diameter: 0.38 mm, external 
diameter: 2.2 mm) were made from Tygon® tubing and were positioned around the right carotid 
artery. The contralateral left carotid artery was used as control. Following carotid injury, the 
animals were maintained on their dietetic regimens for 9 weeks, after which they were killed with 
an overdose of Avertin solution to harvest tissue specimens. Bloody samples were collected at 
sacrifice and analyzed by Fast Protein Liquid Chromatography (FPLC) analysis to identify the level of 
cholesterol in the lipoproteins (on a pool of 5 samples per group). 
 
Histomorphometry 
The collared segment of the right carotid artery and the corresponding segment of the 
contralateral sham-operated artery were collected at sacrifice and processed as previously 
described 19. Briefly, tissue samples were fixed overnight in 4% paraformaldehyde, paraffin 
embedded, and cut transversally into 5 m serial sections. One cross-section every 200 m ≈  was 
stained with hematoxylin and eosin (H and E), photographed under a Zeiss Microscope mounted 
with a digital camera (Nikon Coolpix990) and morphometrically analyzed by using the OPTIMAS 6.2 
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image software (Media Cybernetics, Silverspring, MD). The cross-sectional areas of the intima and 
the media were measured directly and values were used to calculate the intima/media area ratio 
(I/M). The perimeters of the lumen and the external elastic lamina were recorded and used to 
derive the lumen area and the area surrounded by the external elastic lamina (EEL), respectively, 
using the formula perimeter 2  (4π)−1, to normalize for artifacts due to fixation or other steps of 
sample processing, including occasional deformation and potential tissue shrinkage.  
 
Immunostaining and Picrosirius red staining 
Immunostaining for cell type specific markers and Picrosirius red stain were performed on sections 
adjacent to those selected for morphometry. To detect -smooth muscle actin (-SMA)-positive 
vascular SMCs, sections were incubated with an anti -SMA mouse polyclonal antibody (1:200, 
Biovision, Milpitas, CA). For detection of monocytes/macrophages, sections were blocked for 
endogenous peroxidase activity and for non-specific staining and incubated with F4/80 Rabbit mAb 
(1:100; Biovision); sections were then incubated with an avidin-biotin-peroxidase kit (ImmPRESS 
Reagent kit, Vector, Burlingame, CA) and visualized with 3,3-diaminobenzidine (Sigma-Aldrich, 
Milan), followed by hematoxylin counterstaining.  
To detect intimal collagen, sections were stained with Picrosirius red (Direct red 80; Sigma-Aldrich) 
and analyzed under polarized light. Positive areas were determined by computer assisted image 
analysis (OPTIMAS 6.2), and related to total intimal surface area. 
 
Cell culture reagents and antibodies for western blotting 
Dulbecco's Modified Eagle Medium (DMEM), trypsin EDTA, penicillin, streptomycin, nonessential 
amino acid solution, and FBS were from Euroclone (Milan, ITALY). Plates and petri dishes were 
from Corning (Oneonta, New York). PDGF-BB was from Sigma-Aldrich. Molecular weight protein 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
7 
 
standards, SDS, TEMED, ammonium persulfate, glycine, and acrylamide solution (30%T, 2.6%C) 
were obtained from BIO-RAD Laboratories (Hercules, CA). BCA assay for determination of protein 
concentrations was purchased from Thermo Fischer Scientific (Waltham, MA). For Western Blot 
analysis, the following antibodies were used: anti-PCSK9 (Cayman, Tallinn, Estonia), anti-α-tubulin 
(Sigma-Aldrich), anti-LDLR (Abcam, Cambridge, UK), and secondary IRDye800 Goat anti-mouse and 
anti-rabbit (Carlo Erba Reagents, Milan, ITALY). 
 
Isolation and culture of mouse aortic SMCs 
The murine aorta was cleaned from peripheral fat and adventitia. The aorta was dissected 
horizontally and smaller incisions were made longitudinally. The explants were kept in a six-well 
plate and subjected to mild heat fixation for 5-10 seconds. The explants were treated for one hour 
with a sterile solution of collagenases (type II, LS004171 Worthongton Biochemical Corporation, 
NJ) to facilitate the migration of the SMCs from the vessel to the medium. The explants were 
supplemented with fresh DMEM High glucose (3 ml) containing 10% FCS. The presence of vascular 
SMCs was observed within one week. The cells were then trypsinised and plated for subsequent 
studies. For reducing the variability between cell strains, the explants were performed from a pool 
of 4 aortas of PCSK9+/+ or PCSK9-/- mice.  
 
RNA preparation and quantitative real-time PCR 
Total RNA was extracted with the iScript Sample Preparation Buffer cDNA synthesis preparation 
reagents (BIO-RAD laboratories) according to manufacturer’s instructions. Reverse transcription-
polymerase first-strand cDNA synthesis was performed by using the Maxima 1st strand DNA RT-
qPCR (Thermo Fisher Scientific, Waltham, MA, USA). Quantitative real time PCR (qPCR) was then 
performed by using the Kit Thermo SYBR Green/ROX qPCR Master Mix (Thermo Fisher Scientific, 
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Waltham, MA, USA) and specific primers for selected genes. Primer sequences used for qPCR 
analysis are available upon request. The analyses were performed with the ABI Prism® 7000 
Sequence Detection System (Applied Biosystems; Life Technologies Europe BV, Milan, ITALY). PCR 
cycling conditions were as follows: 94°C for 3min, 40 cycles at 94°C for 15s, and 60°C for 1min. 
Data were expressed as Ct values and used for the relative quantification of targets with the ΔΔCt 
calculation 21. 
 
Western Blot Analysis 
Cells were washed twice with PBS and lysed by incubation with a solution of 50 mM Tris pH 7.5, 
150 mM NaCl, 0.5% Nonidet-P40, containing a protease and phosphatase inhibitor cocktails 
(Sigma-Aldrich) for 30 minutes on ice. Cell lysates were then cleared by centrifugation at 14,000 g 
for 10 minutes, and protein concentrations were determined using the BCA protein assay (Thermo 
Scientific, Rockford, IL). Equal amount of total protein per sample were separated by SDS-PAGE 
under reducing conditions, transferred to nitrocellulose membrane (GE Healthcare Little Chalfont, 
Buckinghamshire, UK) and subsequently immunoblotted with primary antibody following 
appropriate secondary fluorescently labeled antibody and acquired with the Odissey FC system (LI-
COR, Nebraska). Quantitative densitometric analysis was performed with Image Studio software 
(LI-COR). 
 
Generation of human PCSK9 expression constructs and retroviral infection 
The retroviral expression plasmid encoding PCSK9-FLAG tag, was constructed using the pBM-IRES-
PURO, expressing the puromycin resistance gene as a selectable second cistron gene, generated 
from the original pBM-IRES-EGFP, generously provided by G.P. Nolan (Stanford University, Stanford, 
CA). Human PCSK9-FLAG tag cDNA was kindly provided by Prof. P. Tarugi (University of Modena) 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
9 
 
and subcloned into retroviral expression plasmid by blunt-end ligation.  
 
Cell proliferation assay 
SMCs were seeded in 24 well tray and incubated with DMEM supplemented with 10% FCS. Cell 
proliferation was evaluated by cell counting after trypsinization of the monolayers with use of a 
Coulter Counter model ZM at different time points. SMC doubling time was computed according to 
Elmore and Swift 22. 
 
Cell migration assay 
The Boyden chamber and the polycarbonate membrane were purchased from Biomap (Milan, 
Italy). The membranes were coated with a 0.1 mg/ml of type I collagen solution (PureCol®, 
Nutacon BV, Leimuiden, The Netherlands) in 0.1 M acetic acid at 37°C. The lower compartments of 
the wells of a modified Boyden chamber were filled (in triplicate) with DMEM containing 0.4% FCS 
in the absence or presence of PDGF-BB, whereas the upper compartments were filled with SMCs 
suspensions containing 106 cells/ml. The chamber was incubated at 37°C for 6 hours. The 
membrane was then carefully removed. Adherent SMCs on the top were eliminated and the 
membrane was stained with the Diff-Quik staining set (Biomap, Agrate Brianza, Milan Italy). The 
number of transmigrated cells was counted in four random high-power fields (HPFs) under high 
magnification (objective lens 20x). 
 
Cytoskeleton staining 
Cells were fixed in 4% paraformaldehyde at room temperature for 10 min, permeabilized in 0.1% 
Triton X-100 in phosphate-buffered saline for 15 min, and incubated with rhodamine-phalloidin 
(Sigma Aldrich, Milan, ITALY). Cytoskeleton staining of cells was analyzed using a fluorescence 
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microscope (Axiovert M220; Zeiss Instruments). 
 
Real-time monitoring of cell morphology and cell proliferation using the iCELLigence system 
The iCELLigence system (ACEA Biosciences Inc, San Diego CA, USA) monitors cellular events in 
realtime by recording the electrical impedance that is correlated with cell number, morphology 
and viability in a given culture well. For analyzing SMCs morphology, 40.000 cells/well were plated 
into the E-Plate L8, and the extent of cell spreading was monitored every 10 minutes for 6 hours 
with iCELLigence. For analyzing SMCs proliferation, instead, 10.000 cells/well were plated into the 
E-Plate L8, and their growth was monitored every hour for 5 days. The assay system expresses 
impedance in arbitrary Cell Index units (Rn-Rb)/4.6; where Rn is the cell-electrode impedance of 
the well when it contains cells and Rb is the background impedance of the well with the media 
alone.   
 
G-LISA assay for Rac1 and RhoA 
The intracellular amount of Rac1-GTP and RhoA-GTP were determined by using the G-LISA assay as 
previously described (Cytoskeleton, Inc Denver, CO, USA) 23-25. 
 
Cell cycle analysis 
Cells were trypsinised and centrifuged. The pellet of cells was washed with fresh PBS and re-
centrifuged. The cells were re-suspended with the permeabilizing buffer (NaCl 100mM, TRIS pH 7.4 
150mM; CaCl2 1mM; MgCl2 0.5mM; NP-40 0.1% containing 5 M Propidium iodide). The analysis 
was performed by flow-cytometry by the use of a FACScanTM flow cytometer and analyzed with BD 
CellQuestTM (both from BD Biosciences, San Jose, CA). 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
11 
 
Analysis of the data 
Statistical analysis was performed using the Prism statistical analysis package version 6.0 
(GraphPad Software, San Diego, CA). Data are given as mean ± SD of 3 independent experiments 
unless otherwise stated. P-values were determined by Student’s t-test. A probability value of 
p<0.05 was considered statistically significant. 
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Results 
Neointimal formation of PCSK9+/+ and PCSK9-/- mice induced by carotid collar placement 
To investigate the potential role of PCSK9 on SMC accumulation in the neointimal hyperplasia in 
response to vascular injury, we took advantage of the previously established “collar” model, based 
on the perivascular placement of a plastic cuff around the right common carotid artery 19. 
Littermates sixteen-week-old PCSK9-/- and PCSK9+/+ were subjected to perivascular carotid collar 
placement. Mice were fed normal chow diet for 9 weeks, after which they were sacrificed for the 
morphometric analysis of the right carotid specimens (n=14 animals per group). Representative 
microphotographs of collar-induced neointima formation are shown in Figure 1. 
In both PCSK9+/+ and -/- mice, collared carotid arteries showed the formation of intimal 
lesions that invaded the lumen region (Figure 1); in contrast, no neointimal formation was 
apparent in sham-operated carotid arteries and no morphological and anatomical differences 
were observed between the two strains (Figure 1). The determination of the morphological 
parameters showed a statistically significant reduction of neointimal formation, measured as 
intima area (23.955±1.832 µm2 vs 12.344±1.668 µm2 for PCSK9+/+ and PCSK9-/- respectively; 
p=0.049) or intima/media ratio (1.380±0.175 vs 0.473±0.090; for PCSK9+/+ and PCSK9-/- 
respectively; p=0.024), in PCSK9-/- mice, compared to PCSK9+/+ (Figure 1B). These differences were 
associated to a tendency of a higher lumen area in PCSK9-/- mice (30.194±4.324 µm2 vs. 
18.283±1.912 µm2), although it did not reach a statistical significance (Figure 1B). Determination of 
total cholesterol levels and lipoprotein distribution by FPLC analysis showed that at sacrifice mean 
serum total cholesterol was lower in PCSK9-/- than in PCSK9+/+ mice (13.6 ± 3.3 mg/dL vs 47.1 ± 8.8 
mg/dL; p<0.05) and mainly associated to HDL particles (Figure 1 C). 
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Immunostaining with anti α-smooth muscle actin (α-SMA) antibody showed that carotid 
lesions of PCSK9+/+ mice had higher relative SMCs accumulation than PCSK9-/- (21.0±7.6% vs. 
10.7±2.0% for PCSK9+/+ and PCSK9-/- respectively; P<0.05) (Figure 2A). Analysis under polarized 
light of picrosirius red stained specimens, showed a higher relative collagen accumulation in 
PCSK9+/+ mice (18.38±7.9% vs. 10.45±9.1% for PCSK9+/+ and PCSK9-/- respectively; P<0.05) (Figure 
2B), while no difference in macrophage content was detected, by immunostaining with anti F4/80 
antibody, between the two groups (Figure 2C). 
 
Determination of differentiation and proliferation of SMCs isolated from PCSK9+/+ and PCSK9-/- mice 
To further investigate the role of PCSK9 on neointimal hyperplasia, we isolated aortic SMCs from 
PCSK9+/+ and PCSK9 -/- mice. As expected SMCs from PCSK9-/- mice did not express PCSK9, while 
western blot analysis clearly showed its expression in SMCs from PCSK9+/+ animals. This difference 
was associated with increased levels of the LDLR in knock-out cells (Figure 3A). Different cell 
morphology was also observed between the two cell strains, with a spindle and elongated shape 
for PCSK9-/- SMCs and a more round morphology for the PCSK9+/+ SMCs (Figure 3B). At passage 
one after isolation, the expression of phenotypic markers were determined by qPCR reaction 
under low serum condition (0.4% FCS). PCSK9-/- SMCs express higher levels of α-SMA (2.24±0.36 
fold; P<0.01) and MHC-II (8.65±1.55 fold) and lower levels of caldesmon (-54±14%; P<0.01) (Figure 
3C). In contrast, no differences were found on SM22α and calponin expression, while an almost 
significant reduction of Col1a1 mRNA levels were found in PCSK9-/- SMCs (-31±11%; P=0.06; Figure 
3C) (Figure 3C).  
Cell proliferation rate was then determined by cell counting experiments and iCelligence 
real time monitoring system (Figure 3D and 3E). Cell number after 3 and 6 days of stimulation with 
10% FCS showed that PCSK9-/- SMCs have a lower proliferation rate than the PCSK9+/+ (doubling 
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time equal to 57.3 ± 2.1 h vs 106.3 ± 4.5 h for PCSK9+/+ and PCSK9-/-, respectively) (Figure 3D). A 
similar difference was also observed by a real-time monitoring of cell growth with the iCelligence 
system, where PCSK9-/- SMCs appeared to slow down their proliferation rate after 60-70 h from 
the stimulation, while the PCSK9+/+ SMCs continuously growth, up to 120 h after stimulation 
(Figure 3D).  
The lower proliferation index of PCSK9-/- SMCs was also observed by analyzing the cell cycle 
progression from a quiescent (0.4% FCS) to a proliferative state in response to PDGF-BB (Figure 4A 
and 4B). In PCSK9-/- SMCs, 24h starvation with medium containing 0.4% FCS determined an 
accumulation of cells in the G0/G1 phase that was significantly higher than wild-type cells  
(76.1±0.5% vs. 69.1±0.6% for PCSK9-/- and PCSK9+/+, respectively; p<0.01). Conversely, the 
stimulation with PDGF-BB determined a greater increase of cells in S phase in PCSK9+/+ (from 
9.8±0.5% to 14.8±0.1 %,  5.0%) compared to PCSK9-/- SMCs (from 5.5±0.7% to 7.5±0.5%,  2.0%).  
Overall, the absence of PCSK9 appears to maintain SMCs in a more contractile phenotype, 
to reduce the expression of the major extracellular matrix protein (collagen type I) and to affect 
cell proliferation.  
 
Reconstitution of PCSK9 in PCSK9-/- SMCs restores the proliferation and phenotypic behavior. 
In order to better define the role of PCSK9 on SMCs biology, we took advantage of retroviral 
vectors, encoding for human PCSK9 FLAG tag, for stabling reconstitute the expression of PCSK9 in 
PCSK9-/- SMCs. Exogenous PCSK9 FLAG tag was detected in PCSK9 reconstituted cells (PCSK9 rec) 
by both using an antibody anti PCSK9 or an antibody anti FLAG, while it was not detectable in the 
control cells transduced with empty retroviral vector (Figure 5A and B). As expected, the 
expression of PCSK9 lowered the LDLR protein levels associated with a significant induction of 
LDLR mRNA levels (Figure 5C and D). Quantification of the SMC phenotypic markers by qPCR 
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analysis revealed that, by re-introducing the PCSK9 gene in the PCSK9-/- SMCs, the expression 
levels of α-SMA were reduced (-56±2%; P<0.01) while a significant induction of caldesmon was 
observed (1.46±0.3 fold; p<0.05; Figure 5E). On the contrary, no significant changes were seen for 
SM22α and Col1a1 (Figure 5E). 
  Reconstitution of PCSK9 by retroviral infection in PCSK9-/- SMCs determined a significant 
increase of cell proliferation rate, as assessed by both cell counting and real time monitoring with 
iCelligence system (Figure 5F and 5G).  
 Thus, the exogenous expression of PCSK9 in SMCs PCSK9-/- almost completely rescue the 
contractile phenotype of SMCs and induces a significant induction of cell proliferation. This 
evidence clearly demonstrates a pro-proliferative action of PCSK9 in primary SMCs. 
 
Effect of PCSK9 on SMC migration  
The determination of the migration capacity of PCSK9+/+ and PCSK9-/- SMCs was then determined 
by using the Boyden’s chamber chemotaxis assay with PDGF-BB as chemotactic agent. As shown in 
Figure 6A, compared to PCSK9+/+ SMCs, PCSK9-/- SMCs expressed lower migratory capacity under 
both basal condition and after PDGF-BB stimulation.  
The reconstitution of PCSK9 in PCSK9-/- SMCs (PCSK9 rec) determined an improvement of 
cell migration capacity both under basal condition and after stimulation with PDGF-BB (Figure 6B). 
These results clearly show that PCSK9 plays a direct role in modulating the migratory capacities of 
mouse SMCs. 
Efficient cell migration requires a profound cytoskeleton re-organization and the formation 
protrusive structures termed lamellipodia, filopodia, invadopodia and podosomes 26. Cytoskeletal 
staining with rhodamine-phalloidin showed that SMCs PCSK9+/+ respond to PDGF-BB stimulation 
by acquiring an elongated morphology and by inducing lamellipodia formation (Figure 6C). On the 
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contrary, SMCs PCSK9-/- appear to be unresponsive to PDGF-BB, showing minor cytoskeletal 
changes in comparison to the basal condition (Figure 5C). The different morphological changes 
observed between the two cell lines were also investigated in real-time with the iCelligence 
system. As shown in Figure 6D, the cell index values did not change over time (up to 6 hours) 
under basal condition in both cell strains. However, the stimulation with PDGF-BB determined a 
profound increase of cell index values in SMCs PCSK9+/+ with a maximal induction after 
approximately 1.5h and 2.5h, while in SMCs PCSK9-/- we observed a significant lower cell index 
values with a maximal pick after approximately 1.5h of stimulation (Figure 6D).  
The determination of the intracellular amount of Rac1 and RhoA, in their active GTP-bound 
form by G-LISA assay, showed that in SMCs PCSK9+/+ Rac1-GTP levels increased in response to 
PDGF-BB, while no effect was seen in SMCs PCSK9-/- (Figure 6E). As expected, PDGF-BB stimulation 
did not induce RhoA activity, however, it is interesting to note that the total amount of RhoA-GTP 
is significantly lower in SMCs PCSK9-/- in comparison to SMCs PCSK9+/+ (Figure 6F).  
Taken together, this evidence suggests that PCSK9 facilitates the response of SMCs to the 
chemotactic action of PDGF-BB, with the formation of lamellipodia protrusion and the activation 
of Rac1.  
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Discussion 
In the present study, we have investigated a possible role of PCSK9 on vascular neointimal 
hyperplasia by using C57BL/6 wild type and PCSK9 knock out mice. The rationale of performing 
this analysis was mainly based on our previous observation that cultured SMCs expressed and 
secreted considerable amount of PCSK9 and that immunostaining with anti PCSK9 antibody 
revealed the presence of PCSK9 in human atherosclerotic plaques in regions occupied by α-actin 
positive cells 17.   
 The main finding of the study is that PCSK9 deficient mice are partially protected from the 
neointimal formation induced by periadventitial carotid placement of a non-occlusive collar. The 
morphometric analysis clearly shows that the difference between the PCSK9+/+ and PCSK9-/- is 
almost exclusively related to the neointimal formation, with no changes in the area of the tunica 
media or in remodeling capacity. By immunohistochemical staining, it was shown that, in both 
groups of animal, the major cellular component of the neointima are smooth muscle α-actin 
positive cells while the macrophage component is minimal. In particular, compared to PCSK9+/+, 
PCSK9-/- mice have a significantly lower percentage of the neointima occupied by SMCs. 
Conversely, no difference were found on macrophage content. Picrosirius red staining also 
showed that, in the absence of PCSK9, there was a lower deposition of fibrillary collagen in the 
neointima, an effect that was then confirmed by the observation that cultured PCSK9-/- SMCs 
express lower levels of collagen 11 mRNA.  
 A limitation of our study is that PCSK9-/- mice have significant lower plasma cholesterol 
levels compared to PCSK9+/+, although in our experimental model neointimal hyperplasia is 
induced in normolipidemic mice. We have previously investigated the influence of 
hypercholesterolemia induced either by diet or genetic modification (apoE knock out mice), on 
neointima formation in the collar model, and clearly showed that cholesterol levels (from 78±14 
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mg/dL up to 1380 mg/dL) did not influence the size of the neointimal lesion but rather the plaque 
composition, with a higher inflammatory component and lipid deposition in hypercholesterolemic 
apoE knock out mice 19. Thus, it is unlikely that the protective effect associated to the absence of 
PCSK9 observed in our study was driven by a lower levels of plasma cholesterol. In addition, we 
did not find any significant direct correlation between total plasma cholesterol level and 
intima/media values (data not shown).  
The role of PCSK9 on atherosclerotic plaque development has been previously addressed 
by using transgenic and knock-out mice for PCSK9 fed hypercholesterolemic diet 27. By crossing 
these mice with LDLR knock-out mice, Denis et al demonstrated that the incidence of PCSK9 on 
atherosclerotic plaque development was entirely dependent on the effect on LDLR and thus LDL 
cholesterol plasma levels 27. On the contrary, the effect of PCSK9 on atherosclerosis appears to be 
independent of the regulation of cholesterol levels when the transgenic expression of PCSK9 was 
evaluated in apoE-deficient mice. In this model, PCSK9 overexpression determined a significant 
increase of atherosclerotic plaque without any significant alteration of cholesterol profile 27. Thus, 
both our analysis and the study by Denis et al suggest a direct vascular effect of PCSK9.   
 As the neointimal hyperplasia is results from both migration and proliferation of SMCs, we 
further investigated the role of PCSK9 in cultured mouse SMCs isolated from PCSK9+/+ and PCSK9-/- 
mice. The direct comparison of SMCs isolated by the two different mouse strains showed that 
freshly isolated PCSK9-/- SMCs expressed higher level of the contractile markers α-actin and MHC-
II, and lower levels of the synthetic markers caldesmon and type I collagen. In addition, this cell 
strain showed a lower proliferative index and migratory capacity in comparison to PCSK9+/+ SMCs. 
This data suggests that PCSK9 is likely to modulate both cell proliferation and migration as well as   
the switch from the contractile to the synthetic phenotype. This was then directly documented by 
reintroducing PCSK9 in PCSK9-/- cells.  This system was employed in order to avoid strain-to-strain 
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differences between cell lines independent of PCSK9. The overexpression of PCSK9 showed an 
even greater positive effect on cell proliferation and migration accompanied by a significant 
modulation of -SMA and caldesmon expression, further confirming the role of PCSK9 on SMCs.  
 The positive effect of PCSK9 on cell proliferation has been previously observed after partial 
hepatectomy in PCSK9-/- mice 28 and in hepatocyte cell line HepG2 following PCSK9 
downregulation by shRNA 29. Moreover, since in tumor cells the positive effect of PCSK9 on cell 
number is also associated with a reduction of apoptosis 29. In our model, the relative contribution 
of lower proliferation versus higher apoptosis rate of SMCs on the less neointimal formation 
observed in PCSK9−/− remains to be determined. 
 The role of PCSK9 on cell migration has not been reported previously, although the effect 
of changes in cholesterol levels in the plasma membrane on cell adhesion and migration has been 
documented 30, 31. In particular, the activity of Rac-1 and Rho-A is sensitive to cholesterol levels 
and distribution in the plasma membrane 32 and statins, by depleting the intracellular cholesterol, 
affects the invasive morphology of breast cancer cells 33. Recruitment of integrins to focal 
adhesions and formation of focal adhesions at the leading edge of cells requires cholesterol 30, 34, 35 
and the formation of specialized cholesterol-containing microdomains called caveolae 36. Thus, it is 
tempting to speculate that the higher expression levels of LDLR, observed in SMCs PCSK9-/-, could 
have been sufficient to alter the cholesterol membrane homeostasis and thus integrin recycling, 
focal adhesion formation, and lamellipodia protrusion to the leading edge of the cells and thus cell 
migration. In line with this hypothesis, we have observed an impairment of Rac1 activation and 
lamellipodia formation in response to PDGF-BB. However, more specific studies are required to 
define the role of PCSK9 on the caveolae formation and integrin recruitment to the cell 
membrane.    
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   In conclusion, in the present study we provide evidence of a direct role of PCSK9 on 
neointimal formation in response to vascular injury whereby its absence determined an 
impairment of SMC proliferation and migration rate, potentially associated with the maintenance 
of a more contractile phenotype. These results unveil a pro-atherogenic role of PCSK9 that merits 
further investigations with the aim of highlighting potential direct benefits of PCSK9 inhibitors on 
atherogenesis and related vascular diseases beyond LDL cholesterol lowering.  
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Figure Legend 
Figure 1.  Histologic appearances and morphometric evaluation of collared and contralateral 
carotid arteries of PCSK9+/+ and PCSK9−/− mice.  
A) Representative hematoxylin and eosin staining of carotid cross-sections from PCSK9+/+ and 
PCSK9−/− mice 9 weeks after collar placement. Control carotid arteries from both PCSK9+/+ and 
PCSK9−/− mice did not show neointima formation. Bars = 100µm. B) Histograms showing the results 
of morphometric analysis. Intima/Media ratio was determined dividing the intimal area by the 
medial area. Lumen and EEL area were calculated using the formula perimeter2 (4π)−1. Data are 
expressed as mean±S.E. Differences between groups were assessed by Student’s t-test, *p<0.05. 
C) FPLC analysis of plasma cholesterol profiles from PCSK9+/+ and PCSK9-/- mice. The average 
cholesterol content of each FPLC fraction is shown. 
 
Figure 2. Composition of collar-induced neointimal lesions of PCSK9+/+ and PCSK9-/- mice.  
A) Representative immunostaining with anti-α-SMA antibody (SMC marker) of cross-sections from 
collared carotids; quantification analysis is reported on the right histogram as percentage of α-
SMA positive area in the intima. B) Representative staining with picrosirius red of fibrillary collagen 
visualized under polarized light; quantification analysis is reported on the right histogram as 
percentage of picrosirius red positive area in the intima. C) Representative immunostaining with 
anti-F4/80 (macrophage marker) antibody of cross-sections from collared carotids; quantification 
analysis is reported on the right histogram as percentage of F4/80 positive area in the intima. Data 
are expressed as mean±S.D. Differences between groups were assessed by Student’s t-test, 
*p<0.05; **p<0.01. 
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Figure 3. Analysis of cell phenotype and proliferation rate of PCSK9+/+ SMCs and PCSK9-/- SMCs.  
A) PCSK9+/+ SMCs and PCSK9-/- SMCs were seeded in DMEM/10% FCS and the day after starved for 
an additional 24h with DMEM containing 0.4% FCS. The protein expression of LDLR, PCSK9 and β-
actin were then evaluated by western blot analysis. B) Morphology of PCSK9+/+ SMCs and PCSK9-/- 
SMCs cultured with DMEM containing 10%FCS. C) Freshly isolated SMCs were cultured for 24h 
with DMEM containing 0.4% FCS. Total RNA was than extracted and smooth muscle markers 
expression levels evaluated by real time PCR. Differences between groups were assessed by 
Student’s t-test, *P<0.05; **P<0.01. D) SMCs PCSK9+/+ and PCSK9-/- were seeded at a density of 
2104/well (48 well tray) and incubated with DMEM supplemented with 10% FCS; 24h later the 
cells were counted with the Coulter Counter, after trypsinization of the monolayers (time 0). The 
same analysis was performed after 3 and 6 days. The cultured media were replaced every 3 days 
for maintaining a proper proliferation stimulus. Each bar represents the mean ± S.D. of triplicate 
dishes. For each time points, differences between groups were assessed by Student’s t-test, 
***P<0.001. E)  Dynamic monitoring of cell proliferation was performed by using the iCelligence 
system. SMCs were cultured at time 0 at the density of 2104/well (E-Plate L8) in DMEM containing 
10%FCS, then the proliferation rate was monitored for 120h (5 days) every 15 minutes. Cell index 
is an adimentional value directly related to the cell number. 
 
Figure 4. Cell cycle analysis of PCSK9+/+ SMCs and PCSK9-/- SMCs in response to PDGF-BB.  
Cells were seeded at a density of 2105 in 35-mm dish and incubated with DMEM supplemented 
with 10% FCS. Twenty-four hours later, the medium was changed with medium containing 0.4% 
FCS to stop cell growth, and the cultures were incubated for 24h. At this time, PDGF-BB (20ng/ml) 
was added and cell cycle analysis performed after 24h. A) Representative flow cytometry analysis 
of PCSK9+/+ SMCs and PCSK9-/- SMCs in the presence or absence of PDGF-BB. B) Percentage of cells 
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in the different cell cycle phases. The percentage of cells in S phase of PCSK9+/+ SMCs and PCSK9-/- 
SMCs after stimulation with PDGF-BB was statistically significant as assessed by Student’s t-test, 
P=0.01. 
 
Figure 5. Analysis of phenotype and proliferation rate after PCSK9 reconstitution of SMCs PCSK9-/-.  
SMCs PCSK9-/- were retrovirally transduced with empty retroviral vector or encoding for human 
PCSK9 FLAG-tag. After puromycin selection, the expression of PCSK9 was evaluated by western 
blot analysis from total cell lysates using an anti-PCSK9 antibody (A) or anti-FLAG antibody (B). 
LDLR expression was evaluated by Western blot analysis (C) or quantitative real time PCR (D). E) 
SMCs were cultured for 24h with DMEM containing 0.4% FCS. Total RNA was than extracted and 
smooth muscle markers expression levels evaluated by real time PCR. Differences between groups 
were assessed by Student’s t-test, *P<0.05; **P<0.01. F) SMCs were seeded at a density of 
2104/well (48 well tray) and incubated with DMEM supplemented with 10% FCS; 24 h later the 
cells were counted with the Coulter Counter, after trypsinization of the monolayers (time 0). The 
same analysis was performed after 3 and 6 days. The cultured media were replaced every 3 days 
for maintaining a proper proliferation stimulus. Each bar represents the mean ± S.D. of triplicate 
dishes. For each time points, differences between groups were assessed by Student’s t-test, 
***P<0.001. G) Dynamic monitoring of cell proliferation was performed by using the iCelligence 
system. SMCs were cultured at time 0 at the density of 2104/well (E-Plate L8) in DMEM containing 
10% FCS, then the proliferation rate was monitored for 120 h (5 days) every 15 minutes. Cell index 
is an adimentional value directly related to the cell number. Rec. stays for PCSK9-/- SMCs 
expressing human PCSK9 FLAG-tag after retroviral infection and puromycin selection, -/- stays for 
PCSK9-/- SMCs retrovirally infected with empty control vector containing the puromycin resistant 
gene.  
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Figure 6. Effect of PCSK9 on SMCs migration in response to PDGF-BB. 
A) PCSK9+/+ SMCs and PCSK9-/- SMCs were cultured for 24h in DMEM containing 0.4% FCS. After 
24h, cells were harvested by trypsinization and the migration measured by Boyden’s chamber 
chemotactic assay by using PDGF-BB as chemotactic agent at the indicated concentrations. 
Transmigrated cells were counted in four random high-power fields (HPFs) under high 
magnification (objective lens 20×). Basal indicates cells incubated in DMEM/0.4% FCS without 
PDGF-BB; Differences between groups were assessed by Student’s t-test, *P<0.05; **P<0.01. B). 
The same analysis described in panel A was performed with PCSK9-/- SMCs and PCSK9 rec SMCs. 
Differences between groups were assessed by Student’s t-test, **P<0.01; ***P<0.001. C) 
Cytoskeletal organization of SMCs were analyzed under basal condition (DMEM/0.4% FCS) or 15 
min. stimulation with PDGF-BB (20 ng/ml). F-actin is stained red with rhodamine-phalloidin while 
nuclei are stained blue with DAPI. D) Morphological changes in PCSK9-/- SMCs and PCSK9+/+ SMCs 
were recorded by iCelligence system under basal condition (DMEM/0.4% FCS) and after 
stimulation with PDGF-BB for 6h. E and F). Intracellular levels of Rac-1-GTP and RhoA-GTP levels 
were determined by G-LISA assay under basal condition (DMEM/0.4% FCS) and after stimulation 
for 5 min. with 20 ng/ml of PDGF-BB. 
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